
Carbocysteine is a premium-grade, white crystalline powder mucolytic therapeutic compound carrying CAS number 638-23-3. Refined under strict industrial quality compliance, this high-purity substance exhibits exceptional disulfide bond cleavage performance. Therefore, it provides reliable viscosity reduction across diverse bronchial secretion formulations. Consequently, it serves as an ideal core choice for manufacturing specialized respiratory syrups, advanced expectorant medicines, and modern clinical supportive care lines globally.
Excellent crystalline solubility performance in aqueous solutions provides a distinct operational edge. In addition, its outstanding biological affinity delivers swift results when engineering modern fast-acting respiratory formulations. This active organic solid operates by breaking disulfide bridges within mucus glycoprotein structures systematically. Thus, it successfully enhances the viscosity reduction profiling of targeted medicinal matrices.
Clearly, it supplies the exact chemical mechanisms required to induce rapid expectorant effects. As a consequence, it achieves this mechanical thinning without altering raw mass density uniformity. Therefore, manufacturing teams can count on highly predictable batch results during formulation runs. In this way, processing parameters remain fully stable across diverse commercial production lines.
Moreover, it assists processing engineers in maintaining strict active concentration uniformity. This chemical balance is critical across high-speed liquid mechanical blending and automated syrup filling lines. Hence, it mitigates trace precipitation risks within automated volumetric dosing machinery. For instance, specialized manufacturing facilities incorporate this refined organic powder safely.
Specifically, it acts as a core compound in targeted respiratory syrup and specialized tablet production cycles. Consequently, it maximizes the technical throughput of automated formulation machinery. Consequently, Zyntex coordinates clean room synthesis paths to eliminate downstream moisture-induced alterations from your factory schedule. As a result, your operational lines suffer zero delays from crystal caking or compound degradation.
This high-purity crystalline active therapeutic compound delivers crucial technical value within these four primary industrial sectors:
Primary mucolytic source used for formulating high-efficiency bronchial expectorant liquids. Therefore, it directly supports optimal viscosity-reduction control lines.
Utilized as a high-purity active base to compound professional clinical-strength tablets. Clearly, it is key for uniform disintegration rates in medicine matrices.
Acts as an essential active standard for manufacturing specialized chronic obstructive pulmonary care formulations. Consequently, it guarantees excellent therapeutic clarity.
Used as a professional reference material for validating advanced protein-cleavage kinetics and cysteine purity. Specifically, it confirms optimal reaction pathways.
| Parameter | Standard Value |
|---|---|
| Product Name | Carbocysteine (Karbosistein) |
| Assay / Purity | Min 98.5% to 101.0% (Pharma Grade) |
| Appearance | White, crystalline powder |
| Specific Rotation | -32.0° to -35.0° |
| CAS Number | 638-23-3 |
⚠️ Safety & Handling: Carbocysteine is a stable therapeutic compound showing predictable physical properties. However, intense continuous inhalation of raw powder dust clouds may trigger moderate respiratory tract irritation. Direct skin contact or ocular exposure can cause transient mechanical irritation. Store in original sealed containers in a cool, dry, and secure area away from heat and strong oxidants. Use chemical-resistant gloves, safety goggles, and a particulate mask during handling. Review the Safety Data Sheet (SDS) for detailed protocols.